Sovran Advisors, LLC Galectin Therapeutics Inc Transaction History
Sovran Advisors, LLC
- $702 Billion
- Q4 2024
A detailed history of Sovran Advisors, LLC transactions in Galectin Therapeutics Inc stock. As of the latest transaction made, Sovran Advisors, LLC holds 186,014 shares of GALT stock, worth $282,741. This represents 0.03% of its overall portfolio holdings.
Number of Shares
186,014Holding current value
$282,741% of portfolio
0.03%Shares
1 transactions
Others Institutions Holding GALT
# of Institutions
112Shares Held
9.93MCall Options Held
3.78MPut Options Held
5.27M-
Vanguard Group Inc Valley Forge, PA2.14MShares$3.25 Million0.0% of portfolio
-
Black Rock Inc. New York, NY1.56MShares$2.38 Million0.0% of portfolio
-
Advisor Group Holdings, Inc. Phoenix, AZ1.18MShares$1.8 Million0.0% of portfolio
-
Geode Capital Management, LLC Boston, MA871KShares$1.32 Million0.0% of portfolio
-
Wealthspire Advisors, LLC New York, NY398KShares$605,5280.0% of portfolio
About GALECTIN THERAPEUTICS INC
- Ticker GALT
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 59,426,000
- Market Cap $90.3M
- Description
- Galectin Therapeutics Inc., a clinical stage biopharmaceutical company, engages in the research and development of therapies for fibrotic, cancer, and other diseases. The company's lead product candidate is belapectin (GR-MD-02) galectin-3 inhibitor, a galactoarabino-rhamnogalacturonan polysaccharide polymer that is in Phase III clinical trial f...